Identifying biomarkers in lung cancer patients in Malaysia
Official title: Biomarker Discovery in Lung Cancer - Malaysia
Run by University of Malaya · NCT06504927 · Data updated 2026-11-12
This study is trying to find specific markers in the blood of lung cancer patients in Malaysia to help doctors better identify high-risk individuals and improve follow-up care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | University of Malaya Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Kuala Lumpur) |
| Status | Recruiting |
| Started | January 16, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 18, 2024 |
| Trial ID | NCT06504927 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 30 and above with COPD or pulmonary nodules who have no previous history of cancer.
✕Probably not a fit
Patients who have received cancer treatment or are currently pregnant or lactating may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify biomarkers and signatures that can differentiate between high-risk individuals and lung cancer patients. It focuses on discovering blood-based biomarkers that serve as adjunct tests to imaging diagnoses, thereby improving patient follow-up. The study hypothesizes that changes in cell-free DNA and RNA expression during disease progression can yield valuable biomarker signatures. Participants will provide blood samples and imaging results to facilitate this research.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and monitoring of lung cancer through blood-based biomarkers.
How similar studies have gone: Other studies have shown promise in using liquid biopsies for cancer detection, indicating that this approach has potential based on existing evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female subjects aged 30 and above. * No previous history of any cancers. * Able to provide X-ray and/or LDCT results. * Have either COPD or pulmonary nodules measuring less than 11mm, or deemed not for biopsy by attending physician * Willing to go back for a follow-up X-ray or LDCT scan in the next clinical follow up as per standard of care. * Willing to provide up to 30mL of blood in month-0 (first visit) and up to 21mL in the next standard of care follow up visit (second visit). Exclusion Criteria: * Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment. * Subject is pregnant or lactating (self-declaration). * Subject is unwilling or unable to provide signed informed consent
Where it's running
-
University of Malaya Medical Centre
Kuala Lumpur, Malaysia Recruiting
Study contacts
- Principal investigator: Mau Ern Poh — University of Malaya
- Study coordinator: Mau Ern Poh
- Email: ernestpoh@gmail.com
- Phone: +60379494422
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.